Antonio Testa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonio Testa has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Antonio Varricchio
Federico II Universitary Hospital of Naples, General Surgery, Italy
1 shared publicationCarlo Iannace
San Giuseppe Moscati Hospital of Avellino, General Surgery and Breast Unit, Italy
1 shared publication- Domenico Lo Conte
General Surgery ASST Santi Paolo e Carlo Milan Italy
1 shared publication - Evaristo Maiello
Medical Oncology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
1 shared publication Francesco Caracciolo
San Giuseppe Moscati Hospital of Avellino, General Surgery and Breast Unit, Italy
1 shared publicationGiuliano Gagliardi
San Giuseppe Moscati Hospital of Avellino, Radiology, Italy
1 shared publication
Latest Publications
- Open Access
- 13 March 2013
- Published by Wiley in Case Reports in Oncological Medicine
- Vol. 2013, 1-4
Cat Scratch Disease Presenting as Breast Cancer: A Report of an Unusual Case
Benign lymphoreticulosis (cat scratch disease, CSD) may have a clinical course that varies from the most common lymphadenitis localized in the site of inoculation, preceded by the typical “primary lesion,” to a context of severe systemic involvement. Among these uncommon clinical aspects, there is mammarian granulomatous lymphadenitis which may appear as a mastitis or a solitary intraparenchymal mass, giving the impression of a breast tumor. In these cases, intensive clinical, instrumental, and laboratory investigations are necessary to exclude malignancy. Because of its rarity, in equivocal cases, it is reasonable to use surgical excision for accurate histological examination. We report a case of CSD of the breast in a 59-year-old woman, analyzing the clinical, histopathological, and instrumental appearance and also performing a literature review.
- 13 March 2013
- Published by Wiley in Case Reports in Oncological Medicine
- Vol. 2013, 1-4
Open AccessCat Scratch Disease Presenting as Breast Cancer: A Report of an Unusual Case
Benign lymphoreticulosis (cat scratch disease, CSD) may have a clinical course that varies from the most common lymphadenitis localized in the site of inoculation, preceded by the typical “primary lesion,” to a context of severe systemic involvement. Among these uncommon clinical aspects, there is mammarian granulomatous lymphadenitis which may appear as a mastitis or a solitary intraparenchymal mass, giving the impression of a breast tumor. In these cases, intensive clinical, instrumental, and laboratory investigations are necessary to exclude malignancy. Because of its rarity, in equivocal cases, it is reasonable to use surgical excision for accurate histological examination. We report a case of CSD of the breast in a 59-year-old woman, analyzing the clinical, histopathological, and instrumental appearance and also performing a literature review.
- 1 January 2009
- Published by S. Karger AG in Oncology
- Vol. 77 (Suppl. 1) , 50-56
Adjuvant Therapy in Colon Cancer
Colon cancer is the second leading cause of cancer death worldwide. Approximately three quarters of patients are diagnosed with disease limited to the bowel wall or surrounding lymph nodes. Over the past decade, significant progress has been made in the treatment of localized colon cancer. The use of adjuvant chemotherapy has improved prognosis in stage III disease, but much work remains to be done in optimizing adjuvant treatment. The FOLFOX4 regimen is now considered standard treatment for stage III disease. Combinations of irinotecan and 5-fluorouracil (5-FU) have not proven to be more effective than 5-FU/folinic acid. In stage II, the value of post-operative treatment remains controversial, but the identification of histopathological and molecular prognostic factors would allow selection of patients who can benefit from adjuvanttreatment. The inclusion of molecular targeted agents in combination regimens with cytotoxins, which have already proven effective in advanced disease, is the main field of development in the most recent protocols of adjuvant therapy.
- 1 January 2009
- Published by S. Karger AG in Oncology
- Vol. 77 (Suppl. 1) , 50-56
Adjuvant Therapy in Colon Cancer
Colon cancer is the second leading cause of cancer death worldwide. Approximately three quarters of patients are diagnosed with disease limited to the bowel wall or surrounding lymph nodes. Over the past decade, significant progress has been made in the treatment of localized colon cancer. The use of adjuvant chemotherapy has improved prognosis in stage III disease, but much work remains to be done in optimizing adjuvant treatment. The FOLFOX4 regimen is now considered standard treatment for stage III disease. Combinations of irinotecan and 5-fluorouracil (5-FU) have not proven to be more effective than 5-FU/folinic acid. In stage II, the value of post-operative treatment remains controversial, but the identification of histopathological and molecular prognostic factors would allow selection of patients who can benefit from adjuvanttreatment. The inclusion of molecular targeted agents in combination regimens with cytotoxins, which have already proven effective in advanced disease, is the main field of development in the most recent protocols of adjuvant therapy.